Better Science, Better Health: New Trial Pathways and Better Patient Data


October 20th, 2014

IMI Round Table (by invitation)


VIP Dinner (by invitation)

October October 21st, 2014, London – Royal College of Physicians



Introduction, Sir Richard Thompson, Immediate Past President, Royal College of Physicians


New Pathways for Development and Better Patient Outcomes

  • George Freeman, Parliamentary Under Secretary of State for Life Sciences, UK Government
  • Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency
  • Paolo Daniele Siviero, Head of Pharmaceutical Policy, Italian Medicines Agency
  • Stephen Whitehead, Chief Executive, ABPI
  • Michel Goldman, Executive Director, IMI
  • Andrew Ward, Pharmaceutical correspondent, Financial Times (Moderator)



New Pathways & New Sources of Evidence. What do we need?

  • Marc Trusheim, MIT Sloan School of Management
  • Finn Børlum Kristensen, Executive Director, Eunetha
  • Jillian Oderkirk, Senior Analyst, Health Division, OECD
  • Olga Solomon, Deputy Head of Unit, European Commission
  • Richard Torbett, Chief Economist, EFPIA
  • Helmut Brand, Jean Monnet Professor of European Public Health, Maastricht University (Moderator)
12:10 Lunch & networking

High Quality Patient Data and MAPPs; Better Patient Outcomes, Faster and Cheaper

  • Duane Schulthess, Managing Director, Vital Transformation
  • Mohammad Al-Ubaydli, CEO, Patients Know Best
  • Joel Haspel, Director Strategy & Business Development EMEA, Oracle Health Sciences
  • Adam Heathfield, Senior Director Global Health and Value Innovation Center, Pfizer
  • Tim Williams, Head of Research, Clinical Practice Research Datalink, MHRA
  • Wendy Currie, Editor, Health Policy and Technology (Moderator)

Blazing Trails – New Development Pathways in Action

  • Sandrine Marreaud, Head of Medical and Pharmacovigilance Department, EORTC
  • Ryan Hohman, Managing Director, Friends of Cancer Research
  • Laura Esserman, Breast Cancer Center Director (I-Spy), University of California San Francisco
  • James Anderson, Director of EU Industry & External Partnerships, GSK
  • Edward Abrahams, President, Personalized Medicine Coalition (Moderator)



Real World Evidence – What works?

  • Ifty Ahmed, CEO, Pow Health
  • Jack Bowman, CEO, Handle My Health
  • John Crawford, Healthcare Industry Leader, IBM Europe
  • Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson
  • Geoff Wilson, HTA Task Force Leader, COCIR
  • Gary Finnegan (Moderator)

The Patient’s Understanding of Benefit Risk

  • Pat Furlong, CEO, Parent Project Muscular Dystrophy
  • Yann Le Cam, CEO, Eurordis
  • Sarah Garner, National Institutes of Clinical Excellence
  • Andrea Beyer, Expert Benefit Risk Assessment
  • Bettina Ryll, Founder, Melanoma Patient Network Europe
  • Alastair Kent, Director, Genetic Alliance UK (Moderator)



Wrap-up from workshop sessions


IMI2: Putting MAPPs Into Practice in Europe

  • Nathalie Seigneuret, Senior Scientific Project Manager, IMI
  • Dr Cornelius Schmaltz, Deputy Head of Unit of the Fighting Infectious Diseases and Global Epidemics unit, European Commission
  • Richard Barker, Director, CASMI
  • Jeremy Haigh, European Chief Operating Officer, Research & Development, Amgen Ltd.
  • Faraz Kermani, Senior Editor Europe, The Pink Sheet (Moderator)

Cocktail Reception

In collaboration with: